Tango Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value
Tango Therapeutics, Inc. (TNGX) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value of $489.00 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue · last filed 2026-08-11
- 2026-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value $489.00M.
- 2026-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value $313.61M.
- 2025-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value $60.72M.
- 2025-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value $59.82M.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value as first filed |
|---|---|---|
| 2026-06-30 | $489.00M 10-Q · filed 2026-08-11 | |
| 2026-03-31 | $313.61M 10-Q · filed 2026-05-13 | |
| 2025-12-31 | $60.72M 10-Q · filed 2026-08-11 | |
| 2025-09-30 | $59.82M 10-Q · filed 2025-11-04 | |
| 2025-06-30 | $20.80M 10-Q · filed 2025-08-05 | |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-12 | |
| 2024-12-31 | $2.16M 10-K · filed 2026-03-05 | |
| 2024-09-30 | $32.78M 10-Q · filed 2024-11-06 | |
| 2024-06-30 | $42.85M 10-Q · filed 2024-08-07 | |
| 2024-03-31 | $37.01M 10-Q · filed 2024-05-08 | |
| 2023-12-31 | $62.64M 10-K · filed 2025-02-27 | $62.64B 10-K · filed 2024-03-18 |
| 2023-09-30 | $87.90B 10-Q · filed 2023-11-08 | |
| 2023-06-30 | $3.77B 10-Q · filed 2023-08-07 | |
| 2023-03-31 | $6.44B 10-Q · filed 2023-05-09 | |
| 2022-12-31 | $24.27B 10-K · filed 2024-03-18 | |
| 2022-09-30 | $4.91B 10-Q · filed 2022-11-10 | |
| 2022-06-30 | $9.64B 10-Q · filed 2022-08-10 | |
| 2022-03-31 | $27.14B 10-Q · filed 2022-05-11 | |
| 2021-12-31 | $51.42B 10-K · filed 2023-03-27 | |
| 2021-09-30 | $69.73B 10-Q · filed 2021-11-09 | |
| 2020-12-31 | $6.64B 10-K · filed 2022-03-28 | $6.63B 10-Q · filed 2021-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |